Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
22.09. | Where Immunome Stands With Analysts | 2 | Benzinga.com | ||
22.09. | Goldman Sachs initiates coverage on Immunome stock with Buy rating | 1 | Investing.com | ||
22.09. | Goldman Sachs startet Coverage für Immunome mit 'Buy' und sieht erhebliches Kurspotenzial | 2 | Investing.com Deutsch | ||
IMMUNOME Aktie jetzt für 0€ handeln | |||||
05.09. | Where Immunome Stands With Analysts | 1 | Benzinga.com | ||
06.08. | Immunome Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
06.08. | Immunome Inc. - 8-K, Current Report | - | SEC Filings | ||
11.06. | Immunome Inc. - 8-K, Current Report | 2 | SEC Filings | ||
19.05. | Immunome stock rating cut to Hold by Boral Capital | 2 | Investing.com | ||
12.05. | Immunome GAAP EPS of -$0.52 beats by $0.14, revenue of $2.93M beats by $2.47M | 1 | Seeking Alpha | ||
12.05. | Immunome Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
12.05. | Immunome Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.11.24 | Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update | 217 | Business Wire | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced... ► Artikel lesen | |
29.10.24 | Immunome, Inc.: Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 | 312 | Business Wire | IM-1021 showed superior potency when compared to a competitor in both mantle cell lymphoma and triple-negative breast cancer preclinical models; IND submission expected in 1Q25 HC74, Immunome's... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MODERNA | 24,120 | +14,69 % | Moderna-Aktie: Kurs heute im Minus (21,2677 €) | Am US-amerikanischen Aktienmarkt liegt die Aktie von Moderna zur Stunde im Minus. Der jüngste Kurs betrug 24,79 US-Dollar. Eine Verbilligung in Höhe von 1,09 US-Dollar müssen derzeit die Aktionäre von... ► Artikel lesen | |
CRISPR THERAPEUTICS | 56,00 | -0,88 % | CRISPR Therapeutics AG: CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress | ||
TEMPUS AI | 75,00 | -0,66 % | Affirm Holdings, Oklo, Tempus AI Are Among Top 10 Large Cap Losers Last Week (Sep. 22- Sep. 26): Are The Others In Your Portfolio? | ||
ONCO-INNOVATIONS | 1,010 | -0,98 % | Onco-Innovations schreitet mit präklinischem Programm fort: Nucro-Technics beginnt mit der Entwicklung von Analysemethoden für die PNKP-Technologie | Vancouver, Kanada - 28. September 2025 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich bekannt zu geben... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,095 | 0,00 % | Looking for the Next Big Pop? Here's Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce | ||
OCULAR THERAPEUTIX | 9,452 | +0,38 % | Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts | ||
MACROGENICS | 1,496 | +2,33 % | MacroGenics, Inc.: MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities | Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement... ► Artikel lesen | |
CORCEPT THERAPEUTICS | 72,76 | +1,31 % | Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym? | ||
CYBIN | 5,150 | 0,00 % | Cybin gibt Update zur Neuropsychiatrie-Plattform und bevorstehenden klinischen Meilensteinen | - Erfolgreich abgeschlossene Aufnahme von 36 Teilnehmern in die Phase-2-Studie zu CYB004, dem DMT-Programm (deuteriertes Dimethyltryptamin, "DMT") des Unternehmens zur
Behandlung der... ► Artikel lesen | |
ULTRAGENYX | 25,800 | +0,78 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President | NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president... ► Artikel lesen | |
ENVERIC BIOSCIENCES | 0,660 | 0,00 % | Enveric Biosciences raises $2.2 million through warrant exercise | ||
BIOARCTIC | 28,600 | +0,42 % | AKTIONÄR-Hot-Stock BioArctic: Nächste Zulassungen | Das neuartige Alzheimer-Medikament Leqembi (Lecanemab) steht immer mehr Menschen rund um den Globus zur Verfügung. Fortan darf das Mittel auch in Australien und in einer weiteren Darreichungsform in... ► Artikel lesen | |
AMNEAL PHARMACEUTICALS | 8,550 | -3,39 % | Amneal Pharmaceuticals, Inc.: Amneal to Report Third Quarter 2025 Results on October 30, 2025 | ||
ABSCI | 3,140 | 0,00 % | Hedge Fund and Insider Trading News: George Soros, Clifford A. Sosin, Bill Ackman, David Tepper, Irenic Capital Management, Citadel Investment Group, Absci Corp (ABSI), Dell Technologies Inc (DELL), and More | ||
4D MOLECULAR THERAPEUTICS | 8,720 | +0,35 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | EMERYVILLE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted... ► Artikel lesen |